|
ICER published an Evidence Report for Covid-19 vaccines yesterday. The report includes four Covid-19 vaccines: Comirnaty® (Pfizer, BioNTech), Spikevax® (Moderna), mNexspike® (Moderna), and Nuvaxovid® (Sanofi).
ICER’s Chief Medical Officer, David Rind, MD, MSc stated:
“Covid-19 infections continue to occur year-round, sometimes leading to serious illness or death. For any preventive care, the goal is always to understand whether the potential benefits outweigh the potential harms. ICER evaluated the evidence for Covid-19 vaccines in 12 US sub-populations. Current evidence suggests that the greatest net benefit of Covid-19 vaccination is in pregnant women; infants aged 6 months to one year; and adults over the age of 65, with the net benefit increasing further with increasing age. Declining rates of serious Covid-19 year over year necessarily create some uncertainties. We hope this report will be a useful resource to policymakers and public health officials as they consider vaccination recommendations for Covid-19 for the 2026-2027 season.”
Register here for a June 25th public meeting on Covid-19 vaccines. An independent appraisal committee will review the findings of the ICER Evidence Report, hear further testimony from stakeholders, and deliberate on the clinical effectiveness, benefits beyond health, and long-term value for money.
|